HIV and TB Screening of PNG Marine Organisms

巴布亚新几内亚海洋生物的艾滋病毒和结核病筛查

• 批准号: 6548583
• 负责人: Chris M. Ireland
• 金额: $ 3.62万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-08-15 至 2005-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6548583
• 关键词: HIV infections; T lymphocyte; animal extract; antiAIDS agent; antitubercular agents; aquatic organism; bioassay; cell line; drug discovery /isolation; geographic site; human genetic material tag; tuberculosis

DESCRIPTION (provided by applicant): This research will be performed primarily at the University of Papua New Guinea, in Port Moresby, Papua New Guinea. The objective of this FIRCA application is to develop a bioassay screening program for AIDS and TB at the University of Papua New Guinea to support discovery of new natural product anti-HIV and anti-TB agents from PNG marine organisms. This program represents an extension of a collaboration between Professors Ireland and Barrows at the University of Utah and Professor Matainaho at the University of Papua New Guinea to discover anticancer agents from PNG marine organisms. Dr. Matainaho is currently doing sabbatical research with Drs. Ireland and Barrows at the University of Utah to learn the "CEM-TART" HIV assay. In this system, replication defective HIV-1 is replicated in specially engineered human T-cells. The T-cell lines and virus have been obtained from the NIH AIDS Research and Reference Reagent Program. Dr. Matainaho will transfer this technology back to the University of Papua New Guinea after he returns from sabbatical. In addition, a screening protocol for anti-TB agents will be established based on the Alamar Blue protocol. In preliminary studies, 126 marine invertebrates were collected in the Milne Bay Province of Papua New Guinea. Extracts of the organisms have been prepared and are ready to be screened in the HIV assay. HIV/AIDS has become a serious health concern in Papua New Guinea. Since the report of the first case in 1987, the number of people infected with HIV/AIDS has increased to an alarming proportion with fears of a possible serious AIDS epidemic. In June 2001, the Papua New Guinea National AIDS Council and Department of Health indicated that 3901 people have tested positive for HIV, with about 1366 confirmed with AIDS. The report however, acknowledged that the estimated HIV prevalence to date may be between 10,000 to 15,000. With a weakened immune system, the problem of tuberculosis related to HIV infection is even a more serious threat and potential cause of death. Tuberculosis is listed as a main cause of death in PNG.

描述（由申请人提供）：这项研究将主要在巴布亚新几内亚莫尔兹比港的巴布亚新几内亚大学进行。 该 FIRCA 申请的目的是在巴布亚新几内亚大学开发艾滋病和结核病的生物测定筛查计划，以支持从巴布亚新几内亚海洋生物中发现新的天然产物抗艾滋病毒和抗结核病药物。该项目是犹他大学爱尔兰教授和巴罗斯教授以及巴布亚新几内亚大学马泰纳霍教授之间合作的延伸，旨在从巴布亚新几内亚海洋生物中发现抗癌剂。 Matainaho 博士目前正在与 Drs. 一起进行休假研究。爱尔兰和巴罗斯在犹他大学学习“CEM-TART”HIV 检测。在这个系统中，复制缺陷型 HIV-1 在专门设计的人类 T 细胞中进行复制。 T 细胞系和病毒获自 NIH 艾滋病研究和参考试剂计划。 Matainaho博士休假结束后将把这项技术传回巴布亚新几内亚大学。此外，还将根据Alamar Blue方案建立抗结核药物的筛选方案。初步研究中，在巴布亚新几内亚米尔恩湾省收集了 126 种海洋无脊椎动物。该生物体的提取物已制备完毕，准备用于 HIV 检测中的筛选。艾滋病毒/艾滋病已成为巴布亚新几内亚的一个严重的健康问题。自1987年报告第一例病例以来，感染艾滋病毒/艾滋病的人数已增加到令人震惊的比例，人们担心可能出现严重的艾滋病流行。 2001年6月，巴布亚新几内亚国家艾滋病委员会和卫生部表示，有3901人的艾滋病毒检测结果呈阳性，其中约1366人确诊患有艾滋病。然而，该报告承认，迄今为止估计艾滋病毒感染人数可能在 10,000 至 15,000 人之间。由于免疫系统较弱，与艾滋病毒感染相关的结核病问题甚至是更严重的威胁和潜在的死亡原因。结核病被列为巴布亚新几内亚的主要死因。